Premium
Effects of interleukin‐2 administration on platelet function in cancer patients
Author(s) -
Oleksowicz Leslie,
Zuckerman Dina,
Mrowiec Zbigniew,
Puszkin Elena,
Dutcher Janice P.
Publication year - 1994
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830450306
Subject(s) - medicine , platelet , administration (probate law) , cancer , function (biology) , interleukin , interleukin 2 , oncology , immunology , cytokine , biology , political science , evolutionary biology , law
Platelet function in 16 patients with metastatlc renal cell carcinoma and melanoma was studied sequentially over the first 96 hr of treatment with moderate and highdose inter‐leukin‐2 (IL‐2). During the first 96 hr of therapy, an increased ex vivo platelet maximal aggregation (MA) response to ADP, epinephrine, and arachidonlc acld was paralleled by a decrease In the peripheral platelet count. Plasma speclmens from patients receiving the moderate dose schedule showed a significant IL‐2 induced secretory response of the platelet α‐granule components β‐thromboglobulin (BTG) and platelet factor 4 (PF4) and the eicosanoid thromboxane B 2 (TBX 2 ) as measured by RIA. The increase in TXB 2 was highly correlated with MA when analyzed by bivariate regression analysls, whereas the addition of PF4 to TXB 2 in a multiple regression analysls further Increased their correlation to MA. The observed decrease In peripheral platelet count correlated significantly with MA and PF4 secretion. High‐dose IL‐2‐treated patlents showed a statistically significant increase in the percentage of large platelets exceeding 12 fl in diameter and platelet responsiveness to hypotonic shock. These observations suggest that IL‐2 therapy results in a reduced peripheral platelet pool, with an increased proportion of the remaining pool of platelets larger, more viable, and actlvated. © 1994 Wiley‐Liss, Inc.